Piper Sandler Just Hiked Humana Target to $254
Piper Sandler just hiked Humana's price target to $254 after a strong Q1 and improving Medicare Advantage margins, si...
Choosing points over cash rebates can lead to greater rewards, especially for travel enthusiasts. Find out why this option is beneficial.
27,389 articlesPiper Sandler just hiked Humana's price target to $254 after a strong Q1 and improving Medicare Advantage margins, si...
As the calendar closes on 2025, Ascendis (ASND) faces the final earnings closeout with questions about cash, pipeline...
Two memory stock stories illustrate a bigger question for investors: should you chase the momentum that Wall Street r...
As AI accelerates, energy and data infrastructure firms are in the spotlight. Here are two stock ideas that could rid...
Oil edges toward a $100 threshold as geopolitical tensions intensify. Four key energy names—Exxon, Chevron, ConocoPhi...
Evaxion's Q1 2026 results shed light on how its AI-driven drug discovery model is translating into collaborations and...
Palantir has seen a sizable pullback, but the real question for patient AI investors is whether this move creates a d...
The summer months offer a quiet window to recalibrate your retirement income plan. Learn practical, actionable steps ...
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
Two iconic brands face different paths to recovery. This deep-dive weighs Nike 12-Year and Lululemon 8-Year dynamics,...
Biotech investing often feels unpredictable. This year, agios stock down year highlights how big investor moves and l...
When bad news hits a stock, investors ask if it’s a bargain. This piece weighs UPS’s challenges against its resilient...